Disclosure Of Entity's Operating Segments [Text Block]

Ascelia Pharma - Filing #678716

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of entity's operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	—	—	- SEK	—	—	—	—	—	—	—	—	- SEK	—	—	—	—
Tax expense (income)	—	—	319,000 SEK	—	—	—	—	—	—	—	—	1 933 SEK	—	—	—	—
Profit (loss) before tax	—	—	109 607 SEK	—	—	—	—	—	—	—	—	133 155 SEK	—	—	—	—
Profit (loss)	- SEK	- SEK	109 288 SEK	—	- SEK	109 288 SEK	109 288 SEK	- SEK	—	- SEK	131 223 SEK	131 223 SEK	131 223 SEK	- SEK	- SEK	- SEK
Assets	—	—	—	87 072 SEK	—	—	—	—	218 569 SEK	—	—	—	—	—	—	—
Liabilities	—	—	—	12 744 SEK	—	—	—	—	37 711 SEK	—	—	—	—	—	—	—
Cash flows from (used in) operating activities	—	—	126 792 SEK	—	—	—	—	—	—	—	—	125 263 SEK	—	—	—	—
Cash flows from (used in) investing activities	—	—	47,000 SEK	—	—	—	—	—	—	—	—	65,000 SEK	—	—	—	—
Cash flows from (used in) financing activities	—	—	936,000 SEK	—	—	—	—	—	—	—	—	1 100 SEK	—	—	—	—
Disclosure of products and services [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]